AN2 Therapeutics (ANTX) Leerink Global Healthcare Conference 2026 summary

Strategic program updates

• Epetraborole is advancing into development for polycythemia vera (PV), leveraging prior clinical and preclinical data showing a specific red cell block without affecting white cells or bone marrow progenitors.

• Phase 2 PV trial will begin dosing in August, with initial data expected in early Q4 and additional readouts through 2027.

• The trial will start with a 10-patient sentinel group at low dose, followed by a 40-50 patient dose-ranging study, and culminate in a double-blind, placebo-controlled phase.

• Dose titration will explore 250-750 mg oral dosing, aiming to individualize based on hematocrit reduction needs.

• Plans are in place to file with Indian regulators this month, expecting clearance in 4-5 months to begin the study.

Clinical rationale and trial design

• Epetraborole’s oral formulation and clean drug-drug interaction profile make it suitable for early-line or combination use in PV, potentially replacing or supplementing phlebotomy.

• The trial design mirrors successful approaches in prior studies, with endpoints including hematocrit control without phlebotomy and patient-reported outcomes (PROs) on fatigue and quality of life.

• Initial dose escalation will be cautious, starting at 250 mg every other day, with modeling suggesting a 5-10% hematocrit reduction in the sentinel cohort.

• The study will be conducted primarily in India for speed and cost-effectiveness, with input from both Indian and U.S. key opinion leaders.

• Patient selection will focus on uniformity, avoiding secondary PV and ensuring comparability to global standards.

Mechanistic insights and efficacy expectations

• Epetraborole has shown a dose-dependent reduction in hematocrit in non-PV patients, with modeling indicating potential to achieve target levels in PV.

• No significant changes in iron stores, ferritin, or white blood cells have been observed in prior studies, suggesting a favorable safety profile.

• The drug may have disease-modifying potential by reducing JAK2V617F allele burden, though this remains to be proven.

• Anemia observed in NTM trials was mild, with hemoglobin reductions remaining within normal ranges and no significant impact on fatigue scores.

• The oral route and stable hematocrit control position epetraborole as a strong candidate for frontline therapy in PV.